Latest News
Beyond Brain Organoids: What Makes a CNS Drug Screening Hit Credible?
Summary: Human iPSC-derived neurons and brain organoids are expanding opportunities for CNS drug screening. However, identifying a promising compound is only the beginning. Creative Biolabs highlights how disease-relevant neuronal models, multiparametric phenotypic...
Latest News
What Happened When We Gave Business Classes Our Real Production Data
At Karviva, we used several Google Sheets to keep track of ingredients, materials, production and orders. As the business grew, keeping those records connected became harder. We needed to plan production more reliably and trace each batch from its ingredients through...
Clinical Trial Results 6 November 2026
The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...
AI in Drug Discovery Is Great. Don’t Forget About AI in Drug Development
Artificial intelligence and the buzz around it feel like they're moving at warp speed. As this acceleration continues, especially in the life sciences, we need to pause and understand the vast differences between two uses of artificial intelligence that couldn’t be...
MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients?
MariTide approval cannot be decided until Amgen files, and a search on 5 November 2026 found no filing announcement. BioSpace reported on 4 November 2026 that the first Phase 3 data are expected in 2027. The same report gave no regulatory filing timeline. Amgen’s...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint
MimiVax and Roswell Park Comprehensive Cancer Center reported topline Phase 2b data on 7 October 2026. The SURVIVE trial tested the survivin peptide vaccine SurVaxM in newly diagnosed glioblastoma. The primary endpoint was overall survival. The full study population...
Digital Twins Need a New Validation Trigger: Drift, Not Deployment
A digital twin commissioned to mirror a manufacturing process is, by design, built to keep learning. It ingests live sensor data, recalibrates its internal parameters, and narrows the gap between what it predicts and what the physical process is actually doing. That's...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
Traditional Botanical Knowledge: A Research Lead, Not a Health Claim
I like to call myself a conduit between ancient healing wisdom and modern life. I came to the US thirty years ago to be trained as a pathologist, but I grew up among generations of herbalists. My family roots and my research background have shaped how I view the...
Digital Validation in Life Sciences: CSA, Annex 11 and Annex 22 in 2026
For most of the past three decades, validating a computerised system in a GMP facility has usually meant paper. Teams compiled binders of test scripts, wet-ink signatures and printed screenshots. That model is now under pressure, and digital validation in life...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...
Healthcare AI Needs Trusted Evidence and Communication Standards
The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...
Younger TAVR Patients Raise the Bar for Long-Term Valve Performance
As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...
Biotech Deal Structure: Upfronts, Milestones and Royalties Explained
On 2 October 2026, Novartis agreed to license an autoimmune candidate from Abogen for $575 million upfront. Abogen’s release said milestones could add up to about $7.2 billion if every option is exercised. Many headlines led with the combined figure of about $7.8...
Lower Drug Prices Mean Little If the Medication Can’t Reach the Resident
The debate over prescription drug costs, in long-term care as elsewhere, often starts and ends with a number. How much did the medication cost before a negotiated price? How much will Medicare pay? What will the patient owe at the pharmacy counter? Those are important...
Pneumococcal Conjugate Vaccine Meets Phase 3 Goals, Two Serotypes Lag
Vaxcyte reported positive topline results from OPUS-1 on Monday 5 October 2026. The pivotal adult Phase 3 tested VAX-31, the company’s 31-valent pneumococcal conjugate vaccine. It is the first of three adult Phase 3 trials to report. The release was datelined San...
Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint
MimiVax and Roswell Park Comprehensive Cancer Center reported topline Phase 2b data on 7 October 2026. The SURVIVE trial tested the survivin peptide vaccine SurVaxM in newly diagnosed glioblastoma. The primary endpoint was overall survival. The full study population...
Digital Twins Need a New Validation Trigger: Drift, Not Deployment
A digital twin commissioned to mirror a manufacturing process is, by design, built to keep learning. It ingests live sensor data, recalibrates its internal parameters, and narrows the gap between what it predicts and what the physical process is actually doing. That's...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
Traditional Botanical Knowledge: A Research Lead, Not a Health Claim
I like to call myself a conduit between ancient healing wisdom and modern life. I came to the US thirty years ago to be trained as a pathologist, but I grew up among generations of herbalists. My family roots and my research background have shaped how I view the...
Digital Validation in Life Sciences: CSA, Annex 11 and Annex 22 in 2026
For most of the past three decades, validating a computerised system in a GMP facility has usually meant paper. Teams compiled binders of test scripts, wet-ink signatures and printed screenshots. That model is now under pressure, and digital validation in life...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...
Healthcare AI Needs Trusted Evidence and Communication Standards
The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...
Younger TAVR Patients Raise the Bar for Long-Term Valve Performance
As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...
Biotech Deal Structure: Upfronts, Milestones and Royalties Explained
On 2 October 2026, Novartis agreed to license an autoimmune candidate from Abogen for $575 million upfront. Abogen’s release said milestones could add up to about $7.2 billion if every option is exercised. Many headlines led with the combined figure of about $7.8...
Lower Drug Prices Mean Little If the Medication Can’t Reach the Resident
The debate over prescription drug costs, in long-term care as elsewhere, often starts and ends with a number. How much did the medication cost before a negotiated price? How much will Medicare pay? What will the patient owe at the pharmacy counter? Those are important...
Pneumococcal Conjugate Vaccine Meets Phase 3 Goals, Two Serotypes Lag
Vaxcyte reported positive topline results from OPUS-1 on Monday 5 October 2026. The pivotal adult Phase 3 tested VAX-31, the company’s 31-valent pneumococcal conjugate vaccine. It is the first of three adult Phase 3 trials to report. The release was datelined San...
Featured Articles
Further News
Who Confirms the Alert Before Dawn?
I practice emergency medicine. Overnight care is where timing funds or fails any sepsis early warning tool. A recommendation that sits unconfirmed for hours is not decision support. It is wallpaper. Confirmation is the intervention Accuracy slides still dominate...
The Model Said No. Who Gets to Overrule It?
In rare tumors, oncologists know the usual story. PD-L1 is a weak compass. Tumor mutational burden is often unavailable. The evidence base was never built. So when MD Anderson investigators revisited biopsies from 84 patients in a phase 2 basket trial of pembrolizumab...
Weekly News Roundup | 05 October 2026
Life science news 5 October 2026: four US approvals, three deals and two UK regulatory items. The FDA approved Emcitate, which it calls the first treatment for MCT8 deficiency. The FDA approved a heart valve that can be expanded as a child grows. AstraZeneca agreed to...
Novartis Licenses Abogen mRNA-Encoded T-Cell Engager for $575m Upfront
Novartis has licensed an mRNA-encoded T-cell engager from Abogen Biosciences of Suzhou, China. Abogen announced the licensing and option agreement through PR Newswire on Friday 2 October 2026. The upfront payment is 575 million US dollars. Milestones could add up to...
Why Periodontitis Matters Beyond Dentistry
In brief: Periodontitis, the advanced form of gum disease, is consistently linked with cardiovascular disease, type 2 diabetes and adverse pregnancy outcomes. Only the diabetes link is supported by treatment trials, in which periodontal therapy lowers HbA1c by about...
Low FODMAP Diet and Disordered Eating in IBS
A new study published in September has reinforced how, for people with IBS who have been taught the low FODMAP diet, uncontrolled digestive symptoms and psychological distress can be linked to disordered eating behaviours. It can help us think about how patients are...
Clinical Trials Roundup | 2 October 2026
The clinical trial results 2 October 2026 span hepatitis delta, wet macular degeneration, Niemann-Pick disease, COVID-19 and skin cancer. Mirum Pharmaceuticals’ brelovitug met its primary endpoint in chronic hepatitis delta. Kodiak Sciences’ Zenkuda and tabirafusp-ted...
Beyond the Scale: Meaningful Follow-Up in GLP-1 Care
A GLP-1 follow-up appointment can produce a clear number without answering the most important question: how is this person doing? Weight remains relevant in obesity care, but a useful review also creates space for symptoms, everyday function and the practical work of...
How AI Is Redefining the Modern Healthcare Consultation
Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...
I’m a Black Gestational Carrier. How People Calculate My Risk Is Wrong
Adding Black maternal-health statistics to data on gestational carriers and calling the sum mine doesn't make it so. The numbers don’t work that way. I’ve carried three pregnancies for other families. I’m also a Black woman. Put those facts beside two well-documented...
Disease Progression Slowing Holds on Function, Misses on Composite
uniQure released four-year results for its Huntington’s disease gene therapy on Tuesday 29 September 2026. The disease progression slowing measured on the composite clinical scale narrowed at 48 months. It missed statistical significance. A second measure, Total...
The Writing Got Cheap. The Checking Did Not
Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













